Evidence map›Paper›PMID 37492092›Full record

ArticleFrontiers in pharmacology2023

Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of

Yingxue Yang, Shutong Chen, Qinghua Wang, Miao-Miao Niu, Yuanqian Qu, Yang Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yingxue YangDepartment of Gastroenterology, The First People's Hospital of Kunshan, Suzhou, China.
Shutong ChenDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Qinghua WangDepartment of Gastroenterology, The First People's Hospital of Kunshan, Suzhou, China.
Miao-Miao NiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Yuanqian QuDepartment of Pathology, Department of Gastrointestinal Surgery, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
Yang ZhouDepartment of Pathology, Department of Gastrointestinal Surgery, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
China Pharmaceutical University · CNNanjing Medical University · CNFirst People's Hospital of Kunshan · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening.

Indexed as

cancerdualtargeting inhibitorshistone deacetylase 1speckle-type POZ proteinstructure-based virtual screening

Identifiers

PMID37492092
PMCPMC10363607
OpenAlexW4383818733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.